A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control. Patients in the trial who received de-escalated therapy experienced fewer short-term side effects than those who received standard therapy. Findings from the study will be presented today at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

The study focused on imaging using fluorodeoxyglucose (FDG) to detect responses to chemoradiation for p16+ oropharynx cancer. While FDG is the most commonly used radiotracer in clinical PET imaging, this trial is the first to report its use as a mid-treatment imaging marker to guide de-escalation for OPC.

Patients in this multi-institution trial had FDG-PET scans to determine their metabolic tumor volume before and midway through treatment. The current analysis reports findings for the first 59 patients accrued to the trial. Those who had tumors with lower metabolic activity before treatment and more than 50% reduction in metabolic tumor volume after two weeks of treatment were de-escalated – specifically, treatment stopped at a total dose of 54 Gy in 27 fractions, rather than the standard total dose of 70 Gy in 35 fractions. All patients received concurrent weekly carboplatin/paclitaxel chemotherapy.

"Advanced imaging helps physicians personalize therapy based on patients' individual tumor characteristics and response to treatment. By incorporating FDG-PET scans before and midway through treatment, we were able to adjust the radiation dose for about half of our patients and reduce their short-term side effects while still focusing on tumor control," said lead author Steven Allen, MD, PhD, a radiation oncology resident at the University of Michigan.

Half of the patients met de-escalation criteria and received the lower radiation dose, resulting in approximately 25% less radiation exposure to the sensitive structures in the head and neck known to be associated with side effects during treatment. Patients in the de-escalated group had significantly less weight loss during treatment (6% vs. 11% from baseline, p<0.001), were less likely to need a feeding tube (1 vs. 7 patients, p=0.037) and had improved swallowing function on a video swallow study administered after treatment (p=0.036).

"We anticipated long-term improvements in side effects, but the short-term improvements were better than expected," said senior author and principal investigator Michelle L Mierzwa, MD, Associate Chair of Clinical Research and Co-Chair of Head and Neck Clinical Trials at the University of Michigan. "Experiencing fewer short-term side effects potentially allows patients to get back to their normal activities more quickly."

###

Dr. Allen will present this study in Plenary Session I on Thursday, February 24, at 1:30 p.m. Mountain time. To access the meeting or schedule interviews with researchers, contact ASTRO's media relations team at [email protected]. The abstract is available online.

This study is supported in part by NIH/NCI grant U01CA183848. Disclosures for Dr. Allen are available online.

This release contains updated study information from the author.

Attribution to the 2022 Multidisciplinary Head & Neck Cancers Symposium requested in all coverage.

Resources for Patients and Caregivers

• Videos: Radiation Therapy for Head and Neck Cancers; (Spanish version), An Introduction to Radiation Therapy; (Spanish version)
• Digital brochure: Radiation Therapy for Head and Neck Cancers
• ASTRO's clinical guidelines
• Additional patient brochures, videos and information on radiation therapy from RTAnswers.org

About the Symposium
The 2022 Multidisciplinary Head and Neck Cancers Symposium takes place February 24-26 at the JW Marriott Phoenix Desert Ridge in Phoenix, Arizona. This two-and-a-half-day meeting for the head and neck cancer community provides up-to-date information on clinical research, treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation for patients with head and neck cancers. A major focus is placed on the multidisciplinary nature of disease management and the incorporation of all treatment modalities to achieve best outcomes. The meeting is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the American Head & Neck Society (AHNS) and the Society for Immunotherapy of Cancer (SITC).

About ASTRO
The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with nearly 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and follow us on social media.